Cargando…
A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis
BACKGROUND: Long-term immunosuppression is often required in myasthenia gravis (MG). There are no published trials using methotrexate (MTX) in MG. The steroid-sparing efficacy of azathioprine (AZA) has been demonstrated after 18-months of starting therapy. However, AZA is considered expensive in Afr...
Autores principales: | Heckmann, Jeannine M, Rawoot, Amanullah, Bateman, Kathleen, Renison, Rudi, Badri, Motasim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170595/ https://www.ncbi.nlm.nih.gov/pubmed/21819556 http://dx.doi.org/10.1186/1471-2377-11-97 |
Ejemplares similares
-
A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
por: Di, Li, et al.
Publicado: (2022) -
Azathioprine/immune-globulin/steroids: COVID-19 and treatment failure in myasthenia gravis: case report
Publicado: (2021) -
Nonmelanoma skin cancer risk awareness in azathioprine‐treated myasthenia gravis patients
por: McGurgan, Iain J., et al.
Publicado: (2015) -
Azathioprine: Myasthenia gravis crisis secondary to COVID-19 pneumonitis: case report
Publicado: (2021) -
Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases
por: Europa, Tarin A., et al.
Publicado: (2022)